Correction
The original article [1] contains two errors in Table 2:
The data values in the rows ‘Disease control rate’ and ‘Objective response rate’ and the columns ‘With adverse events’ and ‘Without adverse events’ have mistakenly been interchanged between columns; the values ‘39 (32.77)’ and ‘6 (5.04)’ should be swapped with the values ‘82 (54.67)’ and ‘11 (7.33)’ respectively.
The value for the row ‘Median progression-free survival (IQR)’ for the ‘HR/OR’ sub-column should be 0.69, not 0.79.
Table 2.
Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib
| Clinical outcomes | With adverse events (n = 150) | Without adverse events (n = 119) | Unadjusted analysis | Multi-adjusted analysisa | ||
|---|---|---|---|---|---|---|
| HR/ORb (95% CI) | P valuec | HR/OR (95% CI) | P valued | |||
| Median overall survival (IQR), days | 169 (96–255) | 103 (58–201) | 0.67 (0.51,0.88) | 0.0039 | 0.64 (0.48,0.84) | 0.001 |
| Median progression-free survival (IQR), days | 86.5 (57–150) | 62 (41–121) | 0.75 (0.58,0.98) | 0.0309 | 0.69 (0.53,0.91) | 0.007 |
| Disease control rate, n (%) | 82 (54.67) | 39 (32.77) | 2.47 (1.46,4.21) | < 0.001 | 2.67 (1.59,4.47) | < 0.001 |
| Objective response rate, n (%) | 11 (7.33) | 6 (5.04) | 1.49 (0.49.5.06) | 0.443 | 1.42 (0.50,4.01) | 0.505 |
Adverse events are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment
HR hazard ratio, OR odds ratio, IQR interquartile range
aAdjusted for sex, every 10-year increase in age, number of metastatic sites and ECOG PS
bHR for overall survival and progression survival; OR for disease control rate and objective response rate
cP values calculated from log-rank test for overall survival and progression survival, and chi-square test for disease control rate and objective response rate
dP values calculated from Cox regression for overall survival and progression survival, and logistic regression for disease control rate and objective response rate
As such, the table displayed ahead shows the correct presentation of Table 2 and should be considered instead.
Footnotes
The original article can be found online at https://doi.org/10.1186/s13045-017-0521-0.
Contributor Information
Pagona Lagiou, Email: plagiou@hsph.harvard.edu.
Jin Li, Email: fudanlijin@163.com.
Reference
- 1.Liu X, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10:153. doi: 10.1186/s13045-017-0521-0. [DOI] [PMC free article] [PubMed] [Google Scholar]